
Inavolisib Plus Palbociclib/Fulvestrant Gains European Approval in PIK3CA-Mutant, HR+/HER2– Advanced Breast Cancer
The combination of inavolisib (Itovebi) with palbociclib (Ibrance) and fulvestrant (Faslodex) won European approval for the treatment of patients with PIK3CA-mutated, estrogen receptor (ER)–positive, HER2-negative, locally advanced or metastatic breast …